StockData
Caris Life Sciences, Inc. logo

Caris Life Sciences, Inc. (CAI) income statement

CAINasdaqServices-Medical LaboratoriesFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 7/3090% above fair value
$19.50−0.44 (-2.21%)

Close on Nov 18, 2026Market cap $5.51BP/E –Yield –

Caris Life Sciences, Inc. income statement

Ratios

Latest available, balances at Sep 30, 2026

Profitability, TTM

Gross margin
–
Operating margin
13.4%
Net margin
9.2%
Return on equity, FY2025
7.1%

Financial strength

Current ratio
6.71
Debt to equity
0.61
Debt to assets
31.3%
Cash to current liabilities
–

Valuation

P/E ratio
–
Price to sales
5.26
Price to book
8.62
Dividend yield
–

See a number that looks wrong?